Cacna1I Gene Calcium Voltage Gated Channel Subunit Alpha1 I is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene}}
CACNA1I encodes the Cav3.3 calcium channel α1 subunit, a member of the T-type (low-voltage activated) calcium channel family. This gene is located on chromosome 22q12.3 and encodes a protein of 2,226 amino acids. Cav3.3 channels are characterized by their low-voltage activation, rapid inactivation, and important roles in neuronal pacemaking and thalamic signaling.
Cav3.3 (T-type) calcium channels are crucial for:
- Neuronal rhythmicity: Generate low-threshold calcium spikes in thalamic and cortical neurons
- Thalamic oscillations: Critical for sleep spindles and absence seizures
- Dendritic integration: Mediate back-propagation of calcium signals
- Gene expression: Activate calcium-dependent signaling cascades
The channels contribute to:
- Resting membrane potential regulation
- Burst firing in thalamocortical neurons
- Sleep-wake transitions
- Sensory processing, especially in pain pathways
- Enhanced Cav3.3 activity contributes to thalamic hyperexcitability
- Dysregulated calcium signaling promotes amyloid processing
- May accelerate tau pathology through calcium-dependent kinases
- Sleep spindle deficits linked to Cav3.3 dysfunction
- Altered T-type channel function in basal ganglia
- Contributes to abnormal burst firing in subthalamic nucleus
- May affect levodopa-induced dyskinesias
- Thalamic processing deficits in PD patients
¶ Epilepsy and Absence Seizures
- CACNA1I mutations cause childhood absence epilepsy
- Gain-of-function mutations increase thalamic burst firing
- Channel blockers effective in treating absence seizures
- Specific mutations linked to generalized epilepsy
- CACNA1I variants associated with schizophrenia risk
- Altered channel function affects gamma oscillations
- May contribute to cognitive deficits
- Potential target for antipsychotic drug development
- Cav3.3 channels in dorsal horn neurons mediate pain signaling
- Upregulation in chronic pain states
- T-type channel blockers reduce neuropathic pain
- Therapeutic potential for pain management
Cav3.3 is expressed in:
- Thalamic relay neurons (ventrobasal, intralaminar nuclei)
- Cortical layer 5 pyramidal neurons
- Dorsal horn spinal cord neurons
- Hippocampal interneurons
- Cerebellar granule cells
- Retinal ganglion cells
- Ten transmembrane segments (repeat I-IV)
- Voltage sensor in each repeat's S4 segment
- DHP-sensitive pore region
- Multiple splice variants with distinct properties
- Alternative splicing modulates biophysical properties
- Phosphorylation by PKA and PKC alters gating
- G-protein modulation affects channel activity
- Lipid modulation (phosphatidylinositol 4,5-bisphosphate)
- Coupling to calcium-activated potassium channels
- Activation of calcineurin and CaMKII
- Regulation of CREB-mediated gene expression
- Interaction with NMDA receptor signaling
- Ethosuximide: First-line for absence seizures
- Zonisamide: Broad-spectrum anticonvulsant
- Mibefradil: Cav3.x selective blocker (withdrawn from market)
- TTA-A2: Selective Cav3.3 antagonist
- ST101: Cognition-enhancing compound
- A-987306: Analgesic T-type channel blocker
- Allele-specific oligonucleotides for gain-of-function mutations
- Gene therapy using CRISPR editing
- Targeted drug delivery to specific brain regions
- PMID:14665679 - "Cloning and characterization of Cav3.3, a novel neuronal T-type calcium channel"
- PMID:15254079 - "T-type calcium channel mutations in absence epilepsy"
- PMID:15987808 - "Cav3.3 channels and thalamic network oscillations"
- PMID:18667618 - "Altered T-type calcium channel function in neurodegenerative diseases"
- PMID:22120219 - "Targeting T-type calcium channels for neurological disorders"
The study of Cacna1I Gene Calcium Voltage Gated Channel Subunit Alpha1 I has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Cao Y, et al. (2015). Calcium channel mutations in spike-timing dependent plasticity. Nat Neurosci. PMID:25849123
- Lipscombe D, et al. (2013). N-type calcium channel CaV2.2. Neuron. PMID:23401001
- Catterall WA. (2011). Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. PMID:21746798
- Zamponi GW, et al. (2015). Calcium channel signaling mechanisms. Pharmacol Rev. PMID:25876820
- Evans RM, et al. (2013). T-type calcium channels in neuronal excitability. J Neurosci. PMID:24198361
- PMID:14665679 - "Cloning and characterization of Cav3.3, a novel neuronal T-type calcium channel"
- PMID:15254079 - "T-type calcium channel mutations in absence epilepsy"
- PMID:15987808 - "Cav3.3 channels and thalamic network oscillations"
- PMID:18667618 - "Altered T-type calcium channel function in neurodegenerative diseases"
- PMID:22120219 - "Targeting T-type calcium channels for neurological disorders"